VivoSeq
Cardiovascular

Varicose Veins

6

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

Varicose veins is an early-stage landscape with 6 programs across 5 companies. The most active players are Helsinn Therapeutics (U.S.), Inc, Ten Sun Pharma Company Limited, Otsuka. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

15/100

Mech. Concentration

100/100

Completion Rate

75/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Helsinn Therapeutics (U.S.), Inc

1 program

Phase 1T

Ten Sun Pharma Company Limited

1 program

ApprovedOtsuka logo

Otsuka

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

ApprovedG

Guizhou Bailing Group Pharmaceutical Co Ltd

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

13

clinical trials

Completed6 · 46%
Not yet recruiting3 · 23%
Withdrawn2 · 15%
Active, not recruiting1 · 8%
Unknown status1 · 8%

Clinical Trials

Trial Activity

13 trials

Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins
Active, not recruiting·RRyazan State Medical University·N/A·NCT06367166·100 enrolled
Polidocanol Foam With or Without Transdermal Laser for Varicose Veins: Randomized Clinical Trial
Not yet recruiting·HHospital Universitario Pedro Ernesto·N/A·NCT07276243·102 enrolled
Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation
Not yet recruiting·—·N/A·NCT07208695·40 enrolled
Calcium Dobesilate After Radiofrequency Ablation for Varicose Veins
Not yet recruiting·—·Phase 4·NCT07390097·250 enrolled
Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt
Completed·BBoston Scientific Corporation·Phase 2·NCT00442364·60 enrolled
An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins
Completed·BBoston Scientific Corporation·Phase 2·NCT00928421·16 enrolled
Impact of Treatment With VENARUS® on the Level of Monocyte Chemoattractant Protein 1 in Varicose Veins Blood
Completed·PPirogov Russian National Research Medical University·N/A·NCT04933591·30 enrolled
Efficacy and Safety of Esarin Gel in Chronic Venous Insufficiency and Varicose Veins
Completed·TTen Sun Pharma Company Limited·Phase 4·NCT02346058·53 enrolled
Investigation Into the Pathophysiology and Treatment of Varicose Veins
Completed·UUniversity of Surrey·N/A·NCT06192472·120 enrolled
Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence
Completed·BBoston Scientific Corporation·Phase 2/3·NCT00758420·77 enrolled
Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate In The Superficial Varicose Veins Treatment
Withdrawn·EEMS·Phase 3·NCT01203397
Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate Cream In The Superficial Varicose Veins Treatment
Withdrawn·EEMS·Phase 3·NCT01426035
is Ultrasound-guided Foam Sclerotherapy a Cost-effective Alternate for Treatment of Varicose Veins?
Unknown status·—·Phase 1·NCT04655417·70 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)